Including debt, the deal, which is expected to close in the third quarter of this year, is valued around $5.2 billion.
Although Anacor currently doesn’t have any products on the market, it has the rights to Kerydin, a treatment for toenail fungus, according to the report. Pfizer believes Kerydin and Anacor’s other offerings would balance Pfizer’s inflammation and immunology products.
More articles on transaction and valuation issues:
Texas Health Resources casts highest bid for bankrupt Fort Worth hospital
Following collapse of Novant, Memorial partnership, HCA enters with offer
HCA to buy yet-to-open Texas hospital for $115M
